Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2–positive metastatic colorectal cancer

Aim: In the single-arm MOUNTAINEER trial (NCT03043313) tucatinib in combination with trastuzumab showed an objective response rate (ORR) of 39.3% in patients with previously treated, HER2+unresectable or metastatic colorectal cancer (mCRC). This study compared the efficacy of tucatinib in combinat...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Claire Watkins, Cyndy Simon, Peter Martin, Regina Leadley, Gabrielle Redhead, Edward Neuberger, Karen Bartley
Format:	Artigo
Sprog:	Inglês
Udgivet:	Becaris Publishing Limited 2026-01-01
Serier:	Journal of Comparative Effectiveness Research
Fag:	colorectal cancer comparative effectiveness matching-adjusted indirect comparison survival
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!